Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.91 USD | -1.81% | +1.55% | +49.18% |
05-03 | Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 | MT |
05-02 | Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.18% | 2.37B | |
+18.49% | 47.02B | |
+48.77% | 41.86B | |
+1.31% | 41.76B | |
-4.27% | 28.8B | |
+11.33% | 26.05B | |
-21.25% | 19.15B | |
+4.65% | 12.55B | |
+27.67% | 12.34B | |
-3.62% | 11.82B |
- Stock Market
- Equities
- KYMR Stock
- News Kymera Therapeutics, Inc.
- B. Riley Adjusts Kymera Therapeutics' Price Target to $31 From $16, Keeps Neutral Rating